AHA: Intensive Strategy for Lowering Systolic BP Beneficial in Type 2 Diabetes

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 20, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Nov. 20, 2024 -- For patients with type 2 diabetes and elevated systolic blood pressure, an intensive-treatment strategy is better than a standard-treatment strategy for incidence of major cardiovascular disease events, according to a study published online Nov. 16 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Yufang Bi, M.D., Ph.D., from the Shanghai Institute of Endocrine and Metabolic Diseases, and colleagues enrolled patients aged 50 years or older with type 2 diabetes, elevated systolic blood pressure, and an increased risk for cardiovascular disease at 145 clinical sites across China to examine effective targets for systolic blood pressure control. Patients were randomly assigned to receive up to five years of intensive treatment targeting systolic blood pressure of less than 120 mm Hg or standard treatment targeting systolic blood pressure of less than 140 mm Hg (6,414 and 6,407 patients, respectively).

The researchers found that at one year of follow-up, mean systolic blood pressure was 121.6 and 133.2 mm Hg in the intensive-treatment and standard-treatment groups, respectively. During a median follow-up of 4.2 years, primary outcome events (nonfatal stroke, nonfatal myocardial infarction, treatment or hospitalization for heart failure, or death from cardiovascular causes) occurred in 393 and 492 patients in the intensive-treatment and standard-treatment groups, respectively (1.65 and 2.09 events per 100 person-years, respectively; hazard ratio, 0.79). The treatment groups had a similar incidence of serious adverse events.

"The benefits of intensive treatment were consistent across all prespecified subgroups," the authors write.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-21 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords